NASDAQ:ZYBT Zhengye Biotechnology (ZYBT) Stock Price, News & Analysis $1.95 -0.09 (-4.41%) Closing price 04:00 PM EasternExtended Trading$1.94 -0.01 (-0.51%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Zhengye Biotechnology Stock (NASDAQ:ZYBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zhengye Biotechnology alerts:Sign Up Key Stats Today's Range$1.85▼$2.1150-Day Range$0.65▼$8.0152-Week Range$0.62▼$13.08Volume147,169 shsAverage Volume4.70 million shsMarket Capitalization$92.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. Read More Zhengye Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreZYBT MarketRank™: Zhengye Biotechnology scored higher than 3% of companies evaluated by MarketBeat, and ranked 902nd out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingZhengye Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageZhengye Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Zhengye Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioZhengye Biotechnology has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.63% of the float of Zhengye Biotechnology has been sold short.Short Interest Ratio / Days to CoverZhengye Biotechnology has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zhengye Biotechnology has recently increased by 417.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZhengye Biotechnology does not currently pay a dividend.Dividend GrowthZhengye Biotechnology does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for ZYBT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zhengye Biotechnology insiders have not sold or bought any company stock.Percentage Held by InstitutionsZhengye Biotechnology has minimal institutional ownership at this time.Read more about Zhengye Biotechnology's insider trading history. Receive ZYBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zhengye Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZYBT Stock News HeadlinesZhengye Biotechnology Regains Nasdaq Minimum Bid Price ComplianceAugust 6, 2026 | tipranks.comWhy Zhengye Biotechnology Holding (ZYBT) Stock Is Up TodayAugust 5, 2026 | quiverquant.comQI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had written off. The stock climbed more than 1,100% over the next 3-4 years, with some subscribers reporting gains of $141,000, $272,000, or more. He believes a similar setup is forming now around what he calls the 'Energy Cube' - a compact nuclear system roughly the size of a shipping container, capable of powering up to 1,000 homes with no emissions, 24 hours a day. Bill Gates, Jeff Bezos, Google, and Microsoft have all backed companies in this space. The Nuclear Regulatory Commission is expected to issue a key approval as early as August - the first of its kind for this technology class in over a decade.August 24 at 1:00 AM | Monument Traders Alliance (Ad)Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | BenzingaJuly 23, 2026 | benzinga.comZhengye Biotechnology Addresses Unusual Nasdaq Trading ActivityJuly 21, 2026 | tipranks.comZhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)July 21, 2026 | msn.comZhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading ActivityJuly 21, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Comments on Unusual Trading ActivityJuly 21, 2026 | globenewswire.comSee More Headlines ZYBT Stock Analysis - Frequently Asked Questions How have ZYBT shares performed this year? Zhengye Biotechnology's stock was trading at $1.15 at the beginning of 2026. Since then, ZYBT shares have increased by 69.6% and is now trading at $1.95. When did Zhengye Biotechnology IPO? Zhengye Biotechnology (ZYBT) raised $6 million in an initial public offering on Tuesday, January 7th 2025. The company issued 1,500,000 shares at $4.00 per share. Kingswood Capital Partners served as the underwriter for the IPO. How do I buy shares of Zhengye Biotechnology? Shares of ZYBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ZYBT's financial health is in the Yellow zone, according to TradeSmith. ZYBT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZYBT Previous SymbolNASDAQ:ZYBT CIK1975641 Webwww.jlzybio.com Phone86-13844801919FaxN/AEmployees278Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.03 Current Ratio1.14 Quick Ratio0.82 Sales & Book Value Annual Sales$16.64 million Price / Sales5.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book2.10Miscellaneous Outstanding Shares47,390,000Free FloatN/AMarket Cap$92.41 million OptionableN/A Beta-2.74 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ZYBT) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
